Clinical trials: Ovarian Tumor
Ovarian Cancer
Ovarian Cancer Individualized Scoring System Scoring System
This project aims at creating an individualized prognostic model using patient characteristics and disease features to determine disease prognosis using machine learning technology.
- Trial name
- OCISS (NCT05496517)
- Where
- 2 sites in Egypt
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Assiut University
Solid Tumor
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
This is a first in human, single arm, open label, Phase 1a/1b study to determine the safety, feasibility, and efficacy of a single dose of NeoTCR-P1 T cells in participants with solid tumors.
- Trial name
- NCT03970382
- Testing
- NeoTCR-P1 adoptive cell therapy, nivolumab, IL-2
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- PACT Pharma, Inc.
Breast Cancer, Non-small Cell Lung Cancer
Study to Evaluate the Safety of Nanoxel M Inj.
Study to evaluate the safety of Nanoxel M inj. administration in patients.
- Conditions
- Breast Cancer, Non-small Cell Lung Cancer, Prostate Cancer, Ovarian Cancer
- Trial name
- NCT04066335
- Where
- South Korea
- Volunteers
- 1,498 people
- Sponsor
- Samyang Biopharmaceuticals Corporation
Polycystic Ovary Syndrome (PCOS), Insulin Resistance Syndrome
Evaluation of MG53 (TRIM72) Levels in Women With Polycystic Ovary Syndrome: An Observational Study
Purpose of the Study: This study is being conducted to examine a protein called MG53 (also known as TRIM72) in women with polycystic ovary syndrome (PCOS).
- Trial name
- PCOSMG53 (NCT07094776)
- Testing
- No intervention (observational study)
- Where
- Turkey (Türkiye)
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Havva Betül Bacak
Ovarian Neoplasm, Fallopian Tube Neoplasms
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
The primary objectives of this study are to evaluate progression-free survival (PFS) by blinded independent central review (BICR) and overall survival (OS) (evaluated independently, as dual primary endpoints) in patients treated…
- Conditions
- Ovarian Neoplasm, Fallopian Tube Neoplasms, Peritoneal Neoplasms
- Trial name
- NCT05257408
- Testing
- Relacorilant 150 mg, Nab-paclitaxel 80 mg/m^2, Nab-paclitaxel 100 mg/m^2
- Where
- 116 sites in United States, Argentina and 12 more
- Volunteers
- 381 people
- Sponsor
- Corcept Therapeutics
Gynecological Malignant Tumor, Solid Tumor
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies
A phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy of BL-B01D1 for injection in patients with multiple solid tumors, including recurrent or metastatic gynecological malignancies.
- Trial name
- NCT05803018
- Testing
- BL-B01D1
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
The main purpose of this study is to: Learn about the safety of ubamatamab and to find out what dose of ubamatamab can be given alone or with cemiplimab to patients with ovarian cancer or cancer of the uterus The study will also…
- Conditions
- Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer
- Trial name
- NCT03564340
- Testing
- Ubamatamab, Cemiplimab, Sarilumab
- Where
- 54 sites in United States, Australia and 8 more
- Volunteers
- 890 people
- Sponsor
- Regeneron Pharmaceuticals
Ovarian Neoplasm
A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer
A supra-additive cytotoxic effect was seen when CAI and paclitaxel were given to human ovarian cancer cells sequentially in tissue culture.
- Trial name
- NCT00001426
- Testing
- Cyclophosphamide, Paclitaxel, Cisplatin
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Ovarian Carcinoma, Recurrent Ovarian Carcinoma
Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy
This clinical trial evaluates the effects a probiotic intervention has on the gut and vaginal microbiome in patients undergoing chemotherapy for ovarian cancer that may have spread from where it first started to nearby tissue…
- Conditions
- Advanced Ovarian Carcinoma, Recurrent Ovarian Carcinoma, Stage II Ovarian Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8
- Trial name
- NCT07144826
- Testing
- Biospecimen Collection, Probiotic, Questionnaire Administration
- Where
- United States
- Volunteers
- 161 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Ovarian Cancer
Minimally Invasive Interval Debulking Surgery in Advanced Ovarian Cancer
In women with advanced epithelial ovarian cancer (AOC), neoadjuvant chemotherapy (NACT) combined with interval cytoreductive surgery and post-operative chemotherapy is an option.
- Trial name
- MISSION-2 (NCT07031908)
- Testing
- Minimally invasive cytoreduction
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
BRCA Mutation, Ovarian Cancer
Prediction of Germline BRCA 1/2 Genes From Healthy Ovaries
The project aims at enhancing performance metrics and prospectively validating a radiogenomics model based on ovarian US images for predicting germline breast cancer susceptibility gene 1 and/or 2 (BRCA) status in women with…
- Conditions
- BRCA Mutation, Ovarian Cancer, Ultrasound Therapy; Complications
- Trial name
- PROBE-II (NCT05769517)
- Testing
- Germinal BRCA
- Where
- Italy
- Volunteers
- 6,465 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Polycystic Ovary Syndrome
Impact of Metformin on In Vitro Fertilization Outcomes in Overweight and Obese PCOS Women
RCT to investigate whether metformin co-treatment would improve IVF outcomes in overweight and obese women with PCOS.
- Trial name
- NCT02910817
- Testing
- Metformin
- Where
- Egypt
- Volunteers
- 102 people
- Sponsor
- Assiut University
Ovarian Cancer, Cholecystolithiasis
Safety of Opportunistic Salpingectomy During Elective Laparoscopic Cholecystectomy.
The knowledge, coupled with epidemiological studies demonstrating lower ovarian cancer rates in women with a history of tubal sterilization has led to recommendations for opportunistic salpingectomy at the time of benign…
- Trial name
- NCT07642791
- Testing
- Opportunistic salpingectomy, Cholecystectomy
- Where
- Switzerland
- Volunteers
- 300 people
- Sponsor
- University of Zurich
Epithelial Ovarian Cancer, Efficacy
Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer
This study is a single-arm, open, multicenter, exploratory clinical study to observe and evaluate the efficacy and safety of fluazoparib combined with apatinib mesylate in the treatment of patients with ovarian cancer.
- Conditions
- Epithelial Ovarian Cancer, Efficacy, Safety, Bone Mineral Density
- Trial name
- NCT06539091
- Testing
- Fluzoparib, Apatinib Mesylate
- Volunteers
- 51 people
- Sponsor
- Anhui Provincial Hospital
Ovarian Cancer, Nonsmall Cell Lung Cancer
First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b
Phase 1b, a study in high grade serous ovarian cancer and nonsmall cell lung cancer to evaluate the safety and clinical activity of the antibody-drug conjugate (ADC) XMT-1592.
- Trial name
- NCT04396340
- Testing
- XMT-1592
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Mersana Therapeutics
Polycystic Ovarian Syndrome
Comparison of Clomid and Lezra With Lezra for Ovulation Induction in Clomid Resistant PCOS Case
Clomiphene citrate resistant i.e failure to ovulate after 6 cycles of ovulation induction effects 15-40% of patients with PCOS.Two treatment groups will be formed one recieving letrozole alone and another recieving CC and…
- Trial name
- NCT06813118
- Testing
- Clomiphene Citrate and letrozole
- Where
- Pakistan
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- HITEC-Institute of Medical Sciences
NSCLC, SCLC
A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
This is a Phase 1/2a, first-in-human, open-label study of JAB-8263, this study has two parts: solid tumor dose escalation and expansion study and hematology tumor dose escalation and expansion study.
- Conditions
- NSCLC, SCLC, CRPC, ESCC
- Trial name
- NCT04686682
- Testing
- JAB-8263
- Where
- China
- Volunteers
- 152 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Breast Cancer
Preservation of Fertility by Ovarian Stimulation Associated With Tamoxifen, Prior Chemotherapy for Breast Cancer
The rates of patients with spontaneous pregnancies reported after breast cancer is between 3 and 7%, particularly because of these treatments.
- Trial name
- PRESAGE (NCT02890082)
- Testing
- Tamoxifen stim in early follicular phase, Tamoxifen stim in late follicular phase, Tamoxifen stim in luteal phase
- Where
- France
- Volunteers
- 102 people
- Sponsor
- Institut Cancerologie de l'Ouest
Bulky Stage IIIC and IV Epithelial Ovarian Cancer, Fallopian Tube Cancer
First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer
The purpose of this study is to evaluate the role of an additional intraperitoneal chemotherapy with cisplatin and etoposide in bulky advanced epithelial ovarian cancer.
- Conditions
- Bulky Stage IIIC and IV Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- AICE (NCT01669226)
- Testing
- PEip (weekly) and TCiv, TCiv
- Where
- 7 sites in China
- Volunteers
- 215 people
- Sponsor
- Shanghai Gynecologic Oncology Group
Cancer Pain
Efficacy of Biofeedback-Based Serious Game for Pain Alleviation in Middle-Aged and Older Ovarian Cancer Patients: A Randomized Controlled Trial
Consistent pain affects most middle-aged and older ovarian cancer patients. Non-pharmacological pain interventions, such as serious games, offer a promising approach to alleviating this pain by providing an effective sense of…
- Trial name
- NCT06612489
- Testing
- biofeedback based dynamic-difficulty game, fixed difficulty game
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine